Jun 27, 2024
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer
Jun 24, 2024
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Jun 05, 2024
Immutep successfully completes institutional placement and institutional component of entitlement offer
Jun 03, 2024
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
May 15, 2024
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
